| Year |
Citation |
Score |
| 2023 |
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, ... ... Elizalde PV, et al. Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Cell Death & Disease. 14: 833. PMID 38102106 DOI: 10.1038/s41419-023-06339-1 |
0.75 |
|
| 2023 |
Flaqué MCD, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo RC, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano MF, Charreau EH, ... ... Elizalde PV, et al. Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Research : Bcr. 25: 133. PMID 37919764 DOI: 10.1186/s13058-023-01735-z |
0.778 |
|
| 2023 |
Proietti CJ, Béguelin W, Díaz Flaqué MC, Cayrol F, Rivas MA, Tkach M, Charreau EH, Schillaci R, Elizalde PV. Corrigendum to "Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer" [Steroids 76 (2011) 381-392]. Steroids. 200: 109312. PMID 37788521 DOI: 10.1016/j.steroids.2023.109312 |
0.794 |
|
| 2023 |
Balañá ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, Elizalde PV. Correction: Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene. 42: 3087. PMID 37684409 DOI: 10.1038/s41388-023-02821-4 |
0.345 |
|
| 2023 |
Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, Dupont A, Rocha D, Fernández EA, Deza EG, Lopez Della Vecchia D, Barchuk S, Figurelli S, Lasso D, Friedrich AD, ... ... Elizalde PV, et al. Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. Journal For Immunotherapy of Cancer. 11. PMID 36889811 DOI: 10.1136/jitc-2022-005325 |
0.787 |
|
| 2022 |
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, ... ... Elizalde PV, et al. Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Cell Death & Disease. 13: 447. PMID 35534460 DOI: 10.1038/s41419-022-04855-0 |
0.795 |
|
| 2021 |
Mercogliano MF, Bruni S, Mauro F, Elizalde PV, Schillaci R. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. Cancers. 13. PMID 33540543 DOI: 10.3390/cancers13030564 |
0.724 |
|
| 2020 |
Chervo MF, Cordo Russo RI, Petrillo E, Izzo F, De Martino M, Bellora N, Cenciarini ME, Chiauzzi VA, Santa María de la Parra L, Pereyra MG, Güttlein LN, Podhajcer OL, Daniotti JL, Dupont A, Barchuk S, ... ... Elizalde PV, et al. Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth. Oncogene. PMID 32843720 DOI: 10.1038/s41388-020-01430-9 |
0.785 |
|
| 2020 |
Madera S, Chervo MF, Chiauzzi VA, Pereyra MG, Venturutti L, Izzo F, Roldán Deamicis A, Guzman P, Dupont A, Roa JC, Cenciarini ME, Barchuk S, Figurelli S, Lopez Della Vecchia D, Levit C, ... ... Elizalde PV, et al. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis. Hormones & Cancer. PMID 32632815 DOI: 10.1007/s12672-020-00392-4 |
0.758 |
|
| 2020 |
Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. Frontiers in Oncology. 10: 584. PMID 32391269 DOI: 10.3389/fonc.2020.00584 |
0.805 |
|
| 2020 |
De Martino M, Tkach M, Bruni S, Rocha D, Mercogliano MF, Cenciarini ME, Chervo MF, Proietti CJ, Dingli F, Loew D, Fernández EA, Elizalde PV, Piaggio E, Schillaci R. Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. Oncoimmunology. 9: 1715767. PMID 32064174 DOI: 10.1080/2162402X.2020.1715767 |
0.767 |
|
| 2019 |
Cordo Russo RI, Chervo MF, Madera S, Charreau EH, Elizalde PV. Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer? Hormones & Cancer. PMID 30656558 DOI: 10.1007/s12672-018-0356-3 |
0.484 |
|
| 2018 |
Proietti CJ, Cenciarini ME, Elizalde PV. Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions. Steroids. 133: 75-81. PMID 29317254 DOI: 10.1016/j.steroids.2017.12.015 |
0.522 |
|
| 2017 |
Mercogliano MF, Inurrigarro G, De Martino M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández EA, Frahm I, Barchuk S, Allemand DH, Figurelli S, Deza EG, Ares S, Gercovich FG, ... ... Elizalde PV, et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. Bmc Cancer. 17: 895. PMID 29281999 DOI: 10.1186/s12885-017-3897-x |
0.792 |
|
| 2017 |
Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino MF, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani V, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, ... ... Elizalde PV, et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis. Cancer Research. PMID 29212856 DOI: 10.1158/0008-5472.Can-17-1327 |
0.526 |
|
| 2016 |
Velásquez LN, Milillo MA, Delpino MV, Trotta A, Mercogliano MF, Pozner RG, Schillaci R, Elizalde PV, Giambartolomei GH, Barrionuevo P. Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway. Immunology and Cell Biology. 95: 388-398. PMID 27811842 DOI: 10.1038/icb.2016.111 |
0.689 |
|
| 2016 |
Elizalde PV, Cordo Russo RI, Chervo MF, Schillaci R. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocrine-Related Cancer. 23: T243-T257. PMID 27765799 DOI: 10.1530/ERC-16-0360 |
0.767 |
|
| 2016 |
Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Gil Deza E, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R. TNFα-induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27698002 DOI: 10.1158/1078-0432.CCR-16-0970 |
0.797 |
|
| 2015 |
Proietti CJ, Izzo F, Díaz Flaqué MC, Cordo Russo R, Venturutti L, Mercogliano MF, De Martino M, Pineda V, Muñoz S, Guzmán P, Roa JC, Schillaci R, Elizalde PV. Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth. Molecular Endocrinology (Baltimore, Md.). 29: 1468-85. PMID 26340407 DOI: 10.1210/me.2015-1170 |
0.797 |
|
| 2015 |
Wiebe JP, Rivas MA, Mercogliano MF, Elizalde PV, Schillaci R. Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride Journal of Steroid Biochemistry and Molecular Biology. 149: 27-34. PMID 25595041 DOI: 10.1016/j.jsbmb.2015.01.004 |
0.775 |
|
| 2014 |
Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. Breast Cancer Research : Bcr. 16: 491. PMID 25479686 DOI: 10.1186/s13058-014-0491-x |
0.815 |
|
| 2014 |
Elizalde PV, Proietti CJ. The molecular basis of progesterone receptor action in breast carcinogenesis. Hormone Molecular Biology and Clinical Investigation. 9: 105-17. PMID 25436702 DOI: 10.1515/hmbci-2011-0129 |
0.525 |
|
| 2013 |
Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo R, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano M, Charreau EH, ... ... Elizalde PV, et al. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Research : Bcr. 15: R118. PMID 24345432 DOI: 10.1186/bcr3587 |
0.828 |
|
| 2013 |
Tkach M, Rosemblit C, Rivas MA, Proietti CJ, Flaqué MCD, Mercogliano MF, Beguelin W, Maronna E, Guzmán P, Gercovich FG, Deza EG, Elizalde PV, Schillaci R. P42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth Endocrine-Related Cancer. 20: 197-212. PMID 23329648 DOI: 10.1530/ERC-12-0194 |
0.809 |
|
| 2012 |
Diaz Flaqué MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. 78: 559-67. PMID 23178160 DOI: 10.1016/j.steroids.2012.11.003 |
0.774 |
|
| 2012 |
Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Flaqué MCD, Beguelin W, Frahm I, Charreau EH, Cassataro J, Elizalde PV, Schillaci R. Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4 + T cells Journal of Immunology. 189: 1162-1172. PMID 22753933 DOI: 10.4049/jimmunol.1102538 |
0.815 |
|
| 2012 |
Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Research : Bcr. 14: R77. PMID 22583478 DOI: 10.1186/bcr3187 |
0.757 |
|
| 2012 |
Schillaci R, Guzmán P, Cayrol F, Beguelin W, DÃaz Flaqué MC, Proietti CJ, Pineda V, Palazzi J, Frahm I, Charreau EH, Maronna E, Roa JC, Elizalde PV. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. Bmc Cancer. 12: 74. PMID 22356700 DOI: 10.1186/1471-2407-12-74 |
0.78 |
|
| 2012 |
Durfort T, Tkach M, Meschaninova MI, Rivas MA, Elizalde PV, Venyaminova AG, Schillaci R, François JC. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model Plos One. 7. PMID 22235273 DOI: 10.1371/journal.pone.0029213 |
0.764 |
|
| 2011 |
Proietti CJ, Béguelin W, Flaqué MCD, Cayrol F, Rivas MA, Tkach M, Charreau EH, Schillaci R, Elizalde PV. Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer Steroids. 76: 381-392. PMID 21184768 DOI: 10.1016/j.steroids.2010.12.008 |
0.786 |
|
| 2010 |
Béguelin W, Flaqué MCD, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3 Molecular and Cellular Biology. 30: 5456-5472. PMID 20876300 DOI: 10.1128/MCB.00012-10 |
0.811 |
|
| 2010 |
Rivas MA, Tkach M, Beguelin W, Proietti CJ, Rosemblit C, Charreau EH, Elizalde PV, Schillaci R. Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation Breast Cancer Research and Treatment. 122: 111-124. PMID 19760502 DOI: 10.1007/s10549-009-0546-3 |
0.831 |
|
| 2009 |
Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Flaqué MCD, Charreau EH, Schillaci R, Elizalde PV. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth Molecular and Cellular Biology. 29: 1249-1265. PMID 19103753 DOI: 10.1128/MCB.00853-08 |
0.818 |
|
| 2008 |
Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R. TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways Experimental Cell Research. 314: 509-529. PMID 18061162 DOI: 10.1016/j.yexcr.2007.10.005 |
0.788 |
|
| 2007 |
Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier Joffé E, Schillaci R, Elizalde PV. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Molecular Endocrinology (Baltimore, Md.). 21: 1335-58. PMID 17440047 DOI: 10.1210/Me.2006-0304 |
0.814 |
|
| 2006 |
Schillaci R, Salatino M, Cassataro J, Proietti CJ, Giambartolomei GH, Rivas MA, Carnevale RP, Charreau EH, Elizalde PV. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway Journal of Immunology. 176: 3426-3437. PMID 16517711 |
0.76 |
|
| 2005 |
Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Molecular and Cellular Biology. 25: 4826-40. PMID 15923602 DOI: 10.1128/MCB.25.12.4826-4840.2005 |
0.78 |
|
| 2005 |
Salatino M, Schillaci R, Proietti CJ, Carnevale R, Charreau EH, Elizalde PV. [Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer]. Medicina. 64: 129-34. PMID 15628299 |
0.78 |
|
| 2004 |
Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene. 23: 5161-74. PMID 15122317 DOI: 10.1038/sj.onc.1207659 |
0.768 |
|
| 2003 |
Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Molecular and Cellular Biology. 23: 1095-111. PMID 12529413 DOI: 10.1128/MCB.23.3.1095-1111.2003 |
0.466 |
|
| 2002 |
Puricelli L, Proietti CJ, Proiettii CJ, Labriola L, Salatino M, Balañá ME, Aguirre Ghiso J, Lupu R, Pignataro OP, Charreau EH, Bal de Kier Joffé E, Elizalde PV. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. International Journal of Cancer. Journal International Du Cancer. 100: 642-53. PMID 12209601 DOI: 10.1002/ijc.10533 |
0.362 |
|
| Show low-probability matches. |